iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://www.ncbi.nlm.nih.gov/pubmed/19760953
Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2009 Jul-Aug;56(93):1117-21.

Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis

Romeo-Gabriel Mihaila  1 , Laurentiu Nedelcu, Ovidiu Fratila, Elena-Cristina Rezi, Carmen Domnariu, Mircea Deac
Affiliations
  • PMID: 19760953
Multicenter Study

Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis

Romeo-Gabriel Mihaila et al. Hepatogastroenterology. 2009 Jul-Aug.

Abstract

Background/aims: Today, there is no ideal treatment for nonalcoholic steatohepatitis. The present study intended to make a multicentric prospective study about the efficiency of lovastatin and pentoxyphyllin administered in patients with nonalcoholic steatohepatitis.

Methodology: 87 patients were included in the present study. The patients diagnosed with nonalcoholic steatohepatitis and dislypidemia were treated for 4 months with lovastatin 10 mg/day and those without dislypidemia with pentoxyphyllin, 400 mg x 3/day. The patients were evaluated clinically and biochemically monthly.

Results: Regarding the lovastatin-treated group, transaminases significantly decreased (p < 0.05), after the first and second month, as well as cholesterolemia (p < 0.001), and the APRI score after 2 months (p = 0.03). In the pentoxyphyllin-treated group, transaminases significantly decreased after 1 month (p < 0.05), and the Forns index after 2 months (p < 0.05).

Conclusions: Both drugs significantly decreased the transaminases. Lovastatin reduced the cholesterolemia in the dislipidemic patients. The decrease of the APRI score suggests that both medicines have benefic effects on the hepatic histology, too.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

LinkOut - more resources